Search
ganaxolone (Ztalmy)
Indication:
- treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency
Dosage:
- if < 28 kg
- start: 6 mg/kg PO TID (18 mg/kg/day)
- maximum: 21 mg/kg TID (63 mg/kg/day)
- if > 28 kg
- start: 150 mg TID (450 mg daily)
- maximum: 600 mg TID (1800 mg daily)
Oral suspension 50 mg/mL
Pharmacokinetics:
- 99% protein-bound in serum
- terminal half-life for ganaxolone is 34 hours
- metabolized by CYP3A4/5, CYP2B6, CYP2C19, & CYP2D6
- metabolites eliminated in feces 55%, urine 18%
Adverse effects:
- somnolence, sedation
- pyrexia,
- salivary hypersecretion
- seasonal allergy
Mechanism of action:
- GABA-A receptor positive modulator
Interactions
drug adverse effects of anticonvulsants
monitor with anticonvulsants
General
anticonvulsant
Database Correlations
PUBCHEM cid=6918305
References
- 1HIGHLIGHTS OF PRESCRIBING INFORMATION
Ztalmy (ganaxolone) oral suspension
https://marinuspharma.com/wp-content/uploads/2022/03/prescribing-information.pdf